ALK and non-small cell lung carcinoma: A real-world study separately analyzed data from patients with and without baseline brain metastases, showing that the median OS for ALK-positive NSCLC patients with baseline brain metastases was 27.1 months after first-line ALK tyrosine kinase inhibitor (TKI) treatment, while it was 36.9 months for patients without brain metastases (10).